Search Results
Your search for ,WHo matches 20833 pages
Showing 901 - 950Can R-CHOP–Like Therapy Effectively Treat Late-Relapse DLBCL?
Late relapse of diffuse large B-cell lymphoma (DLBCL) may represent a new lymphoma arising from a common precursor cell that is essentially chemotherapy-naive. Treatment with curative intent using a second-line regimen like R-CHOP (rituximab cyclophosphamide, doxorubicin, prednisone, and...
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both...
Salpingectomy During Other Abdominal Surgeries May Lower Ovarian Cancer Risk
Fallopian tube removal performed during other abdominal surgeries could reduce the risk of ovarian cancer incidence among women who have already completed their families, according to a recent study published by Kather et al in PLOS Medicine. Background Ovarian cancer is the third most common...
Does Brain MRI Surveillance Benefit Asymptomatic Patients With Stage IV Breast Cancer?
Researchers have found that asymptomatic brain metastases may be more common in patients with stage IV breast cancer than previously understood, according to a recent study published by Ahmed et al in Neuro-Oncology. The findings suggest that physicians may need to reconsider current screening...
CheckMate 7FL: Neoadjuvant Immunochemotherapy in ER-Positive, HER2-Negative Breast Cancer
A phase III trial has shown adding the PD-1 inhibitor nivolumab to anthracycline- and taxane-based chemotherapy that patients receive ahead of surgery may improve breast cancer cure rates. CheckMate-7FL involved 510 patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer,...
Tiragolumab Plus Atezolizumab/Bevacizumab in Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma
In a phase Ib-II study (MORPHEUS-Liver) reported in The Lancet Oncology, Finn et al found that the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab/bevacizumab improved objective response rate in patients with unresectable, locally advanced, or metastatic hepatocellular...
Talimogene Laherparepvec May Effectively Reduce Basal Cell Carcinoma Size Prior to Surgical Resection
Treatment with the oncolytic virus talimogene laherparepvec may be effective in patients with basal cell carcinoma, according to a novel study published by Ressler et al in Nature Cancer. Background Although basal cell carcinoma—which typically occurs in chronically sun-exposed areas such as the...
Fecal Microbiota Transplantation Following ASCT
Oral fecal microbiota transplantation may be a feasible and safe option to prevent graft-vs-host disease in patients with hematologic malignancies undergoing allogeneic stem cell transplant (ASCT), according to a recent report published by Reddi et al in Nature Communications. The findings built on ...
BOREAS Trial: Navtemadlin Demonstrates Clinical Benefit in JAK Inhibitor–Refractory Myelofibrosis
The oral MDM2 inhibitor navtemadlin is the first single agent to demonstrate significant efficacy in JAK (Janus kinase) inhibitor–refractory myelofibrosis, achieving improvements in spleen volume, symptoms, and biomarkers, according to data presented at the 2024 American Society of Hematology (ASH) ...
Case 2: Moderate Chronic GVHD
This is Part 2 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the management of moderate...
Case 1: Acute GVHD in a Patient With Lymphoma
This is Part 1 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the first-line treatment of...
UICC‘s New World Cancer Day Campaign Calls for Fundamental Shift in Cancer Care Delivery
The Union for International Cancer Control (UICC) has introduced the new 2025 to 2027 United by Unique campaign, calling for a fundamental shift in cancer care and health systems across the world toward a people-centered approach in light of World Cancer Day. World Cancer Day takes place on...
Early-Stage Classic Hodgkin Lymphoma
“It isn’t the mountains ahead to climb that wear you out; it’s the pebble in your shoe.” —Muhammad Ali Long-term survival in early-stage classic Hodgkin lymphoma (cHL) was first made possible by the introduction of the mantle and inverted Y fields of radiotherapy in the 1960s. The addition of...
T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or -Ultralow Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ...
Clearance of Driver Mutations after Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis
In a German single-center study reported in The New England Journal of Medicine, Gagelmann et al determined that clearance of driver mutations after allogeneic hematopoietic stem-cell transplantation was associated with better outcomes in patients with myelofibrosis. Study Details The study...
Pinpointing Contributing Factors in Response to Posttransplant Donor Lymphocyte Infusion in Patients With AML
Researchers have identified factors that could determine whether donor lymphocyte infusion—a type of adoptive cell therapy—will result in remission among patients with acute myeloid leukemia (AML) who have relapsed following allogeneic hematopoietic stem cell transplant (HSCT), according to a...
Novel Combination Targeted Therapies, Chemotherapy in BRAF-Mutated Metastatic Colorectal Cancer
First-line treatment with the targeted therapies encorafenib and cetuximab plus a modified leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) chemotherapy regimen may be effective in patients with BRAF V600E–mutated metastatic colorectal cancer, according to recent findings presented by Kopetz et ...
New Findings on Aspirin and Risk of Colorectal Cancer Recurrence
According to one of the first biomarker-driven randomized study in people with nonmetastatic colorectal cancer, taking 160 mg of aspirin daily after treatment ends may reduce the risk of cancer recurrence in patients with cancers that harbor a PI3K mutation. These mutations are common to many types ...
New Research Explores Blood Test to Determine Prognosis, Benefit of Celecoxib in Stage III Colon Cancer
Previous research has shown that nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin and COX-2 inhibitors, may reduce the risk of developing colon cancer. A recent CALGB/SWOG study revealed that adding celecoxib to FOLFOX chemotherapy improved disease-free survival in patients with...
EULAR: Balancing Treatment Risks for Inflammatory Arthritis and Cancer
The European Alliance of Associations for Rheumatology (EULAR) introduced new points to consider surrounding the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer, according to recent recommendations published by Sebbag et al in the Annals of the...
Muscular Strength, Cardiorespiratory Fitness May Be Linked to Lower Risk of Mortality in Patients With Cancer
Muscular strength and cardiorespiratory fitness may be associated with a lower risk of all-cause mortality in patients with cancer, according to a recent study published by Bettariga et al in the British Journal of Sports Medicine. The findings indicated that a tailored exercise regimen may improve ...
Some Patients With Low-Risk Ductal Carcinoma In Situ May Be Able to Avoid Surgery
Active monitoring appears to be a safe strategy for the management of some patients with low-risk ductal carcinoma in situ (DCIS), proving noninferior to guideline-concordant management of this patient population (ie, surgery with or without radiation therapy). After 2 years, the rate of invasive...
Getting a Lung Cancer Diagnosis Was Shocking
For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...
AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma
Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...
AALL1731 Trial: Adding Blinatumomab to Standard Chemotherapy Improves Outcomes in Pediatric B-Cell ALL
Results of a phase III study suggest that the addition of the immunotherapy agent blinatumomab—a bispecific T-cell engager targeting CD19—to standard chemotherapy may help to prevent relapse in more children with B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer,...
Imlunestrant Alone or With Abemaciclib: An All-Oral Targeted Therapy for ER-Positive Advanced Breast Cancer
The investigational next-generation oral selective estrogen receptor degrader (SERD) imlunestrant improved progression-free survival both as monotherapy in patients with ESR1 mutations and in combination with the CDK4/6 inhibitor abemaciclib regardless of ESR1 mutational status in patients with...
Everolimus/Lanreotide vs Everolimus in Gastroenteropancreatic Neuroendocrine Tumors
A recent study found that a combination of the mTOR inhibitor everolimus and the hormone-blocking drug lanreotide extended progression-free survival compared with everolimus alone for people with some types of neuroendocrine tumors in the pancreas or gastrointestinal tract. The research will be...
Does a New Blood-Based Screening Test Accurately Detect Colorectal Cancer Risk?
Colorectal cancer is the second most common cause of cancer-related deaths in the United States. This year, it’s expected that more than 53,000 individuals will die of the disease. Although screening for the cancer through colonoscopy or sigmoidoscopy is effective in detecting the disease, nearly...
New Study Identifies Potential Dose-Dependent Relationship Among Alcohol Consumption, HBV-Associated Cirrhosis, Hepatocellular Carcinoma
Investigators may have established a dose-dependent model of alcohol consumption on the risks of hepatitis B virus (HBV)-associated cirrhosis and hepatocellular carcinoma, according to a recent study published by Wu et al in the Journal of Clinical and Translational Hepatology. The quantitative...
ASCO Thanks Drs. Bertagnolli, Rathmell for Their Service Leading NIH, NCI
ASCO has applauded Monica M. Bertagnolli, MD, FASC, FASCO, for her service as the 17th Director of the National Institutes of Health (NIH) and Kimryn Rathmell, MD, PhD, for her work as the 17th Director of the National Cancer Institute (NCI). “ASCO would like to extend our deepest gratitude to Dr....
FDA Approves Datopotamab Deruxtecan-dlnk for Advanced HR-Positive, HER2-Negative Breast Cancer
On January 17, the U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Datroway), a TROP-2–directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC1+, or...
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma
On January 16, the U.S. Food and Drug Administration (FDA) granted traditional approval to the Bruton’s tyrosine kinase inhibitor acalabrutinib (Calquence) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem...
FDA Approves Sotorasib With Panitumumab for KRAS G12C–Mutated Colorectal Cancer
On January 16, the U.S. Food and Drug Administration (FDA) approved the KRAS G12C inhibitor sotorasib (Lumakras) with the monoclonal antibody panitumumab (Vectibix) for adult patients with KRAS G12C–mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior ...
AACR Expresses Sincere Appreciation After NIH Director Monica M. Bertagnolli, MD, Steps Down
The American Association for Cancer Research (AACR) expressed its gratitude to Monica M. Bertagnolli, MD, for her outstanding service to the United States during her 14-month tenure as Director of the National Institutes of Health (NIH). Background Dr. Bertagnolli recently announced that she will...
Risks of Preterm Birth, Low Birth Weight, Birth Defects Among Children Born to Young Men With Cancer
The risk of having children who experience preterm birth and low birth weight—but not birth defects—may be increased among male adolescents and young adults with cancer, according to a recent study published by Murphy et al in the Journal of the National Cancer Institute. Background Prior research...
MRI and Biopsy May Reduce Treatment Delays for Muscle-Invasive Urothelial Carcinoma
Multiparametric magnetic resonance imaging (MRI) and biopsy may speed up the time to correct treatment among patients with a muscle-invasive urothelial carcinoma, according to a recent study published by Bryan et al in the Journal of Clinical Oncology. Background Usual tests for muscle-invasive...
Adjuvant T-DM1 in Patients With HER2-Positive Breast Cancer: Long-Term Results of the KATHERINE Trial
Adjuvant treatment with the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) may improve survival in patients with high-risk HER2-positive breast cancer and residual invasive disease, according to long-term findings from the phase III KATHERINE trial published by Geyer et al in The New...
FDA Proposes Significant Step to Reduce Nicotine Levels in Cigarettes, Tobacco Products
The U.S. Food and Drug Administration (FDA) issued a proposed rule that, if finalized, would make cigarettes and certain other combusted tobacco products minimally or nonaddictive by limiting the level of nicotine in those products. If the rule is finalized, the United States would be the first...
Even Low Levels of ctDNA May Be Linked to Recurrence Risk in Early Lung Cancer, Study Finds
Lung cancer is the second most common cancer in the United States, but high recurrence rates persist for patients with early-stage disease. A recent study published by Black et al in Nature Medicine has found that even very low traces of circulating tumor DNA (ctDNA) may be linked to increased...
Study Finds Travel Distance to Lung Cancer Screening Facilities Differs by Race and Ethnicity
Lung cancer is the second most common cancer, excluding skin cancer, diagnosed in men and women in the United States. And despite advances in treatment for the disease, which have led to improved survival rates, lung cancer remains the leading cause of cancer mortality in the United States, with...
Potential of RAD51 Testing in Tailoring Treatment Strategies in Early Breast Cancer
The RAD51 biomarker may help to tailor treatment strategies in patients with early breast cancer, according to a recent study published by Villacampa et al in Clinical Cancer Research. Background “A key objective of research focused on early-stage breast cancer is to identify biomarkers that can...
Effects of Obesity on Survival Outcomes Following Cancer Diagnosis in Pediatric Patients
Pediatric patients with cancer who have obesity at the time of diagnosis may face an elevated risk of mortality, according to a recent study published by Sassine et al in Cancer. Study Methods and Results In the retrospective study, investigators examined data from the Cancer in Young People in...
AI May Enhance Cervical Cancer Detection
Artificial intelligence (AI) could improve screening for cervical cancer, enhancing accuracy and efficiency, according to a recent review article published by Wu et al in Cancer Biology & Medicine. The report, authored by a team of researchers from the Chinese Academy of Medical Sciences and...
Therapeutic De-escalation in Breast Cancer: Can Omitting Axillary Surgery Match Survival While Improving Patient Outcomes?
Omitting axillary surgery may be an option for some patients with early-stage breast cancer, according to a study reported by Reimer et al in The New England Journal of Medicine. Previous studies, such as the SOUND trial, have indicated that avoiding an axillary procedure in patients with small...
NCCN Joins International Meeting to Improve Cancer Care in the Middle East North Africa Region
The National Comprehensive Cancer Network (NCCN) announced that the organization participated in a 2-day meeting at the Middle East North Africa (MENA)–NCCN Regional Coordinating Center. Background The MENA-NCCN Regional Coordinating Center is supported by the Ministry of National Guard Health...
Medicare Advantage vs Traditional Medicare: Cost Differences in Cancer Drugs
A new study examining the use of high-cost drugs among patients with colorectal cancer and non–small cell lung cancer (NSCLC) found those insured through Medicare Advantage received less expensive cancer drugs compared to others on traditional Medicare. The findings were published by Bradley et al...
Novel AI Platform May Help Identify Patients Likely to Benefit Most From Clinical Trials
Researchers have demonstrated that a novel artificial intelligence (AI)-based platform could aid physicians and patients in assessing the benefit from a particular therapy being tested in a clinical trial, according to a recent study published by Orcutt et al in Nature Medicine. The AI platform may ...
ORACLE Test May Predict Survival in Early Stages of Lung Cancer
The ORACLE test may be capable of predicting lung cancer survival at the point of diagnosis more effectively than currently used clinical risk factors, according to a recent study published by Biswas et al in Nature Cancer. The findings could help physicians make more informed treatment decisions...
Adjuvant Tamoxifen Reduces 15-Year Risk of Recurrence in ‘Good Risk’ DCIS Without Radiation Therapy
Adjuvant tamoxifen was associated with a reduced risk of 15-year ipsilateral breast cancer recurrence as well as invasive ipsilateral breast cancer recurrence in patients with “good-risk” ductal carcinoma in situ (DCIS) who omitted radiation therapy after breast-conserving surgery, according to a...
Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Heinzerling et al found that primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemoradiotherapy (with or without adjuvant immunotherapy) was associated with activity in patients with locally advanced...
